Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(5-6):831–837. doi: 10.1038/sj.bjc.6990133

Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line

X F Hu 1, A Slater 1, D Rischin 1, P Kantharidis 1, J D Parkin 1, J Zalcberg 1
PMCID: PMC2362657  PMID: 10070877

Abstract

The effects of 4-demethoxydaunorubicin (idarubicin, IDA) and MX2, a new morpholino-anthracycline, on up-regulation of the MDR1 gene in the low-level multidrug resistant (MDR) cell line CEM/A7R were compared at similar concentrations (IC10, IC50and IC90) over a short time exposure (4 and 24 h). The chemosensitivity of each drug was determined by a 3-day cell growth inhibition assay. Compared with epirubicin (EPI), IDA and MX2 were 17- and eightfold more effective in the CEM/A7R line respectively. No cross-resistance to 5-FU was seen in the CEM/A7R line. Verapamil (5 μM) and PSC 833 (1 μM), which dramatically reversed resistance to EPI in the CEM/A7R line, had no sensitizing effect on the resistance of this line to MX2, but slightly decreased resistance to IDA. The sensitivity to 5-FU was unchanged by these modulators. The induction of MDR1 mRNA expression by IDA, MX2 and 5-FU was analysed by Northern blotting and semiquantitatively assessed by scanning Northern blots on a phosphorimager. The relative level of MDR1 expression was expressed as a ratio of MDR1 mRNA to the internal RNA control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). IDA, MX2 and 5-FU differentially up-regulated MDR1 mRNA in the CEM/A7R line in a dose-dependent manner. Both IDA and MX2 induced MDR1 expression within 4 h. 5-FU up-regulated MDR1 expression only when drug exposure was prolonged to 24 h. Based on MRK 16 binding, flow cytometric analysis of P-glycoprotein (Pgp) expression paralleled the increase in MDR1 mRNA levels. For the three anthracyclines, the increase in MDR1 expression was stable in cells grown in the absence of drug for more than 3 weeks after drug treatment. The induction of MDR1 expression by 5-FU was transient, associated with a rapid decrease in the increased Pgp levels which returned to baseline 72 h after the removal of 5-FU. This study demonstrates that MDR1 expression can be induced by analogues of anthracyclies not pumped by Pgp, and that this induction appears to be stable despite a 3-week drug-free period. © 1999 Cancer Research Campaign

Keywords: drug resistance, induction of MDR1 expression, anthracycline analogues, Pgp expression, drug accumulation

Full Text

The Full Text of this article is available as a PDF (150.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beketic-Oreskovic L., Durán G. E., Chen G., Dumontet C., Sikic B. I. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst. 1995 Nov 1;87(21):1593–1602. doi: 10.1093/jnci/87.21.1593. [DOI] [PubMed] [Google Scholar]
  2. Berman E. A review of idarubicin in acute leukemia. Oncology (Williston Park) 1993 Oct;7(10):91-8, 104; discussion 104-7. [PubMed] [Google Scholar]
  3. Berman E., McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood. 1992 Jun 15;79(12):3267–3273. [PubMed] [Google Scholar]
  4. Bosch I., Croop J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta. 1996 Oct 9;1288(2):F37–F54. doi: 10.1016/0304-419x(96)00022-4. [DOI] [PubMed] [Google Scholar]
  5. Carella A. M., Carlier P., Pungolino E., Resegotti L., Liso V., Stasi R., Montillo M., Iacopino P., Mirto S., Pagano L. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group. Leukemia. 1993 Feb;7(2):196–199. [PubMed] [Google Scholar]
  6. Chaudhary P. M., Roninson I. B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 1993 Apr 21;85(8):632–639. doi: 10.1093/jnci/85.8.632. [DOI] [PubMed] [Google Scholar]
  7. Chen G., Jaffrézou J. P., Fleming W. H., Durán G. E., Sikic B. I. Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res. 1994 Sep 15;54(18):4980–4987. [PubMed] [Google Scholar]
  8. Chin K. V., Chauhan S. S., Pastan I., Gottesman M. M. Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ. 1990 Aug;1(8):361–365. [PubMed] [Google Scholar]
  9. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  10. Consoli U., Priebe W., Ling Y. H., Mahadevia R., Griffin M., Zhao S., Perez-Soler R., Andreeff M. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood. 1996 Jul 15;88(2):633–644. [PubMed] [Google Scholar]
  11. Del Poeta G., Stasi R., Aronica G., Venditti A., Cox M. C., Bruno A., Buccisano F., Masi M., Tribalto M., Amadori S. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood. 1996 Mar 1;87(5):1997–2004. [PubMed] [Google Scholar]
  12. Deuchars K. L., Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin Oncol. 1989 Apr;16(2):156–165. [PubMed] [Google Scholar]
  13. Dumontet C., Duran G. E., Steger K. A., Beketic-Oreskovic L., Sikic B. I. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res. 1996 Mar 1;56(5):1091–1097. [PubMed] [Google Scholar]
  14. Fardel O., Lecureur V., Daval S., Corlu A., Guillouzo A. Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem. 1997 May 15;246(1):186–192. doi: 10.1111/j.1432-1033.1997.t01-1-00186.x. [DOI] [PubMed] [Google Scholar]
  15. Ferrandis E., Bénard J. Activation of the human MDR1 gene promoter in differentiated neuroblasts. Int J Cancer. 1993 Jul 30;54(6):987–991. doi: 10.1002/ijc.2910540621. [DOI] [PubMed] [Google Scholar]
  16. Gekeler V., Beck J., Noller A., Wilisch A., Frese G., Neumann M., Handgretinger R., Ehninger G., Probst H., Niethammer D. Drug-induced changes in the expression of MDR-associated genes: investigations on cultured cell lines and chemotherapeutically treated leukemias. Ann Hematol. 1994;69 (Suppl 1):S19–S24. doi: 10.1007/BF01757350. [DOI] [PubMed] [Google Scholar]
  17. Gonzalez Manzano R., Versanvoort C., Wright K., Twentyman P. R. Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line. Eur J Cancer. 1996 Nov;32A(12):2136–2141. doi: 10.1016/s0959-8049(96)00263-8. [DOI] [PubMed] [Google Scholar]
  18. Grogan T. M., Spier C. M., Salmon S. E., Matzner M., Rybski J., Weinstein R. S., Scheper R. J., Dalton W. S. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood. 1993 Jan 15;81(2):490–495. [PubMed] [Google Scholar]
  19. Hargrave R. M., Davey M. W., Davey R. A., Kidman A. D. Development of drug resistance is reduced with idarubicin relative to other anthracyclines. Anticancer Drugs. 1995 Jun;6(3):432–437. doi: 10.1097/00001813-199506000-00011. [DOI] [PubMed] [Google Scholar]
  20. Horichi N., Tapiero H., Sugimoto Y., Bungo M., Nishiyama M., Fourcade A., Lampidis T. J., Kasahara K., Sasaki Y., Takahashi T. 3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks. Cancer Res. 1990 Aug 1;50(15):4698–4701. [PubMed] [Google Scholar]
  21. Hu X. F., Martin T. J., Bell D. R., de Luise M., Zalcberg J. R. Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res. 1990 May 15;50(10):2953–2957. [PubMed] [Google Scholar]
  22. Hu X. F., Slater A., Wall D. M., Kantharidis P., Parkin J. D., Cowman A., Zalcberg J. R. Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. Br J Cancer. 1995 May;71(5):931–936. doi: 10.1038/bjc.1995.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hu X. F., Slater A., Wall D. M., Parkin J. D., Kantharidis P., Zalcberg J. R. Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line. Clin Cancer Res. 1996 Apr;2(4):713–720. [PubMed] [Google Scholar]
  24. Hu X. F., de Luise M., Martin T. J., Zalcberg J. R. Effect of cyclosporin and verapamil on the cellular kinetics of daunorubicin. Eur J Cancer. 1990;26(7):814–817. doi: 10.1016/0277-5379(90)90159-q. [DOI] [PubMed] [Google Scholar]
  25. Kohno K., Sato S., Takano H., Matsuo K., Kuwano M. The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun. 1989 Dec 29;165(3):1415–1421. doi: 10.1016/0006-291x(89)92761-7. [DOI] [PubMed] [Google Scholar]
  26. McKenna S. L., Padua R. A. Multidrug resistance in leukaemia. Br J Haematol. 1997 Mar;96(4):659–674. doi: 10.1046/j.1365-2141.1997.d01-2095.x. [DOI] [PubMed] [Google Scholar]
  27. Michieli M., Michelutti A., Damiani D., Pipan C., Raspadori D., Lauria F., Baccarani M. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. Leuk Lymphoma. 1993 Feb;9(3):255–264. doi: 10.3109/10428199309147379. [DOI] [PubMed] [Google Scholar]
  28. Nielsen D., Maare C., Skovsgaard T. Cellular resistance to anthracyclines. Gen Pharmacol. 1996 Mar;27(2):251–255. doi: 10.1016/0306-3623(95)02013-6. [DOI] [PubMed] [Google Scholar]
  29. Nooter K., Sonneveld P. Clinical relevance of P-glycoprotein expression in haematological malignancies. Leuk Res. 1994 Apr;18(4):233–243. doi: 10.1016/0145-2126(94)90025-6. [DOI] [PubMed] [Google Scholar]
  30. Osborn M. T., Chambers T. C. Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem. 1996 Nov 29;271(48):30950–30955. doi: 10.1074/jbc.271.48.30950. [DOI] [PubMed] [Google Scholar]
  31. Rohlff C., Glazer R. I. Regulation of multidrug resistance through the cAMP and EGF signalling pathways. Cell Signal. 1995 Jul;7(5):431–443. doi: 10.1016/0898-6568(95)00018-k. [DOI] [PubMed] [Google Scholar]
  32. Ross D. D., Doyle L. A., Yang W., Tong Y., Cornblatt B. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance. Biochem Pharmacol. 1995 Nov 9;50(10):1673–1683. doi: 10.1016/0006-2952(95)02069-1. [DOI] [PubMed] [Google Scholar]
  33. Rothenberg M. L., Mickley L. A., Cole D. E., Balis F. M., Tsuruo T., Poplack D. G., Fojo A. T. Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia. Blood. 1989 Sep;74(4):1388–1395. [PubMed] [Google Scholar]
  34. Shustik C., Dalton W., Gros P. P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med. 1995;16(1):1–78. doi: 10.1016/0098-2997(94)00040-a. [DOI] [PubMed] [Google Scholar]
  35. Tanimura H., Kohno K., Sato S., Uchiumi T., Miyazaki M., Kobayashi M., Kuwano M. The human multidrug resistance 1 promoter has an element that responds to serum starvation. Biochem Biophys Res Commun. 1992 Mar 16;183(2):917–924. doi: 10.1016/0006-291x(92)90571-2. [DOI] [PubMed] [Google Scholar]
  36. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981 May;41(5):1967–1972. [PubMed] [Google Scholar]
  37. Ueda K., Clark D. P., Chen C. J., Roninson I. B., Gottesman M. M., Pastan I. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem. 1987 Jan 15;262(2):505–508. [PubMed] [Google Scholar]
  38. Watanabe M., Komeshima N., Naito M., Isoe T., Otake N., Tsuruo T. Cellular pharmacology of MX2, a new morpholino anthracycline, in human pleiotropic drug-resistant cells. Cancer Res. 1991 Jan 1;51(1):157–161. [PubMed] [Google Scholar]
  39. Zalcberg J. R., Hu X. F., Wall D. M., Mirski S., Cole S., Nadalin G., De Luise M., Parkin J. D., Vrazas V., Campbell L. Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line. Int J Cancer. 1994 May 15;57(4):522–528. doi: 10.1002/ijc.2910570414. [DOI] [PubMed] [Google Scholar]
  40. de Vries E. G., Zijlstra J. G. Morpholinyl anthracyclines: option for reversal of anthracycline resistance. Eur J Cancer. 1990;26(6):659–660. doi: 10.1016/0277-5379(90)90110-f. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES